Behrens G M N
Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Internist (Berl). 2012 Oct;53(10):1187-94. doi: 10.1007/s00108-011-2973-6.
HIV therapy is able to achieve complete viral suppression in up to 90% of patients. Thus, most patients will benefit from long-term effective and tolerable therapy combinations. Antiretroviral therapy, however, can still lead to side effects, is costly, and its success is dependent on sufficient health system resources and access to different drug combinations. Established tools in prevention and novel approaches to avoid spread of HIV infection are crucial to combat the epidemic. Recent advances in research about how drug regimens stop viral transmission ("treatment as prevention"), how the immune system defends against HIV (natural killer cells, broad neutralizing antibodies), and how cellular factors restrict viral replication are import milestones on the long way to stopping the global epidemic and to fostering vaccine development.
艾滋病病毒疗法能够使高达90%的患者实现病毒完全抑制。因此，大多数患者将受益于长期有效且耐受性良好的治疗组合。然而，抗逆转录病毒疗法仍可能导致副作用，成本高昂，其成功依赖于充足的卫生系统资源以及获得不同药物组合的途径。既定的预防工具和避免艾滋病毒感染传播的新方法对于抗击这一流行病至关重要。在关于药物方案如何阻止病毒传播（“治疗即预防”）、免疫系统如何抵御艾滋病毒（自然杀伤细胞、广泛中和抗体）以及细胞因子如何限制病毒复制的研究方面取得的最新进展，是在阻止全球疫情蔓延和推动疫苗研发的漫长道路上的重要里程碑。
